EyePoint Pharmaceuticals

Site Investigator, Evan Dunn, M.D., shares more about the global Phase 3 #LUGANO clinical trial and potential impact of a more durable #WetAMD treatment option for patients.?? ? EyePoint Pharmaceuticals has partnered with Dr. Dunn to share his own views for educational purposes only; his statements are not intended as medical advice.

#EnvisionYourFuture at #EYPT!?? ? We’re hiring a Director of Process Development for our Watertown, MA location. #ApplyToday if you meet the following qualifications:?? - Ph.D. in Chemical Engineering?? - 7+ years of experience in #Pharma development?? - Expert in Quality by Design (QbD)?? - Success leading product and process development from Phase 2/3 through commercialization?? - Understanding of GMP manufacturing? ?? #Careers #DEI #MassJobs #LifeSciences https://lnkd.in/eg2kXqfD Theresa DiBiase, Sherry Jenkins McHale, Andrea Bauer, Ph.D. RAC

#EYPT is in Singapore for Asia-Pacific Vitreo-Retina Society (APVRS) 2024!? ? Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI will present the results from our Phase 2 #DAVIO2 clinical trial for our lead investigational therapy in #WetAMD and share how the data informed the design of our Phase 3 #LUGANO and #LUCIA program.? ? We look forward to a great meeting connecting with renowned retina specialists to explore the latest #RetinalDisease advancements.? ? #APVRS2024?

#EnvisionYourFuture at #EYPT! We’re #Hiring a Senior Quality Systems Compliance Specialist with a bachelor’s degree to drive compliance activities for development, laboratory and #Manufacutring operations.?? ? #ApplyToday if you are a certified auditor with:?? - Extensive knowledge of US and EU cGMP regulations and guidance?? - 7+ years of FDA regulated industry experience?? - 5+ years of auditing experience??? ? https://lnkd.in/eWKEdTyi?? ? #HybridWork #LifeSciences #Careers #DEI Theresa DiBiase, Sherry Jenkins McHale, Melissa Bedarian, Sean Richards

This year, Team #EYPT was excited to participate in the Wellable Biotech Challenge for a month-long journey of healthy competition and commitment to wellness! Alongside other #Biotech companies, we spent the month prioritizing our physical and mental well-being through a series of webinars, a steps challenge, and more, as part of our commitment to empowering a healthy workplace. Thank you to everyone who participated in the challenge! Visit our website to learn more about EYPT’s commitment to supporting our employees’ health and wellbeing: https://lnkd.in/diZNHUB??

WE’RE #HIRING | Finance Planning & Analysis Manager????? ?? Our team is looking for a Finance Planning & Analysis Manager with 4+ years of experience and #biotech knowledge. As a member of the FP&A team at #EYPT, you will be a core contributor in financial forecasting, reporting, systems & analysis for the R&D and G&A functions.?? ? #ApplyToday for an exciting opportunity to provide support and leadership on key strategic business initiatives at a high growth organization!? ? #EnvisionYourFuture #Careers #DEI #LifeSciences? ? https://lnkd.in/eRuWUWxb ??Udaya S., Theresa DiBiase, Sherry Jenkins McHale

“The new manufacturing facility in Northbridge will support EyePoint’s mission by fostering inclusive collaboration as well as transformational innovation.” – Karli Hanson, Manager, Supply Chain The opening of our new state-of-the-art #Manufacturing facility in #Northbridge, MA is a major milestone for #EYPT that will accelerate our #Clinical development and future #Commercial production for our investigational sustained delivery therapy in #WetAMD and #DME. ??Watch the video below to learn more. #InvestorNews #RetinaPipeline #RetinalDiseases

#EYPT’s vision? To develop innovative therapeutics to improve the lives of patients with serious #RetinalDiseases this #DiabeticEyeDiseaseAwarenessMonth and every day. ? With the topline data from our #VERONA clinical trial coming in 2025, we remain committed to addressing the current treatment paradigm for #DME. To learn more about EYPT’s pipeline, visit https://lnkd.in/eN4BpBGi

David Boyer, MD shares more about the current #WetAMD treatment burden and Phase 3 #LUGANO and #LUCIA clinical trials.? ? EyePoint Pharmaceuticals has partnered with Dr. Boyer to share his own views for educational purposes only; his statements are not intended as medical advice.?

Our President & CEO, Jay S. Duker, M.D. is in London for the Jefferies London Healthcare Conference! He will share the latest on our #RetinaPipeline and how we are innovating for serious #RetinalDieases, including #WetAMD and #DME. #TuneIn tomorrow for his presentation!?